These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Intramuscular aripiprazole in the control of agitation. Currier GW; Citrome LL; Zimbroff DL; Oren D; Manos G; McQuade R; Pikalov AA; Crandall DT J Psychiatr Pract; 2007 May; 13(3):159-69. PubMed ID: 17522559 [TBL] [Abstract][Full Text] [Related]
3. Predictors of aripiprazole treatment continuation in hospitalized patients. Coley KC; Fabian TJ; Kim E; Ammerman DK; Scipio TM; Saul MI; Kim MS; Whitehead R; Ganguli R J Clin Psychiatry; 2008 Sep; 69(9):1393-7. PubMed ID: 19012819 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. Daniel DG; Currier GW; Zimbroff DL; Allen MH; Oren D; Manos G; McQuade R; Pikalov AA; Crandall DT J Psychiatr Pract; 2007 May; 13(3):170-7. PubMed ID: 17522560 [TBL] [Abstract][Full Text] [Related]
5. Intramuscular aripiprazole in the acute management of psychomotor agitation. De Filippis S; Cuomo I; Lionetto L; Janiri D; Simmaco M; Caloro M; De Persis S; Piazzi G; Simonetti A; Telesforo CL; Sciarretta A; Caccia F; Gentile G; Kotzalidis GD; Girardi P Pharmacotherapy; 2013 Jun; 33(6):603-14. PubMed ID: 23505124 [TBL] [Abstract][Full Text] [Related]
6. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Mintzer JE; Tune LE; Breder CD; Swanink R; Marcus RN; McQuade RD; Forbes A Am J Geriatr Psychiatry; 2007 Nov; 15(11):918-31. PubMed ID: 17974864 [TBL] [Abstract][Full Text] [Related]
7. Mirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4-week open-label parallel-group study. Schüle C; Baghai TC; Eser D; Hecht S; Hermisson I; Born C; Häfner S; Nothdurfter C; Rupprecht R World J Biol Psychiatry; 2007; 8(2):112-22. PubMed ID: 17455104 [TBL] [Abstract][Full Text] [Related]
8. Aripiprazole: effectiveness and safety under naturalistic conditions. Di Lorenzo R; Amoretti A; Forghieri M; Fiorini F; Genedani S; Rigatelli M Exp Clin Psychopharmacol; 2007 Dec; 15(6):569-75. PubMed ID: 18179310 [TBL] [Abstract][Full Text] [Related]
9. Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. Zimbroff DL; Marcus RN; Manos G; Stock E; McQuade RD; Auby P; Oren DA J Clin Psychopharmacol; 2007 Apr; 27(2):171-6. PubMed ID: 17414241 [TBL] [Abstract][Full Text] [Related]
10. Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study. Findling RL; Kauffman RE; Sallee FR; Carson WH; Nyilas M; Mallikaarjun S; Shoaf SE; Forbes RA; Boulton DW; Pikalov A J Clin Psychopharmacol; 2008 Aug; 28(4):441-6. PubMed ID: 18626272 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. Kane JM; Barnes TR; Correll CU; Sachs G; Buckley P; Eudicone J; McQuade R; Tran QV; Pikalov A; Assunção-Talbott S J Psychopharmacol; 2010 Jul; 24(7):1019-29. PubMed ID: 20008446 [TBL] [Abstract][Full Text] [Related]
13. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study. Lin CH; Lin SH; Jang FL J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699 [TBL] [Abstract][Full Text] [Related]
14. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials. Glick ID; Mankoski R; Eudicone JM; Marcus RN; Tran QV; Assunção-Talbott S J Affect Disord; 2009 May; 115(1-2):18-26. PubMed ID: 19230981 [TBL] [Abstract][Full Text] [Related]
15. A prospective, open-label study of Aripiprazole mono- and adjunctive treatment in acute bipolar depression. Dunn RT; Stan VA; Chriki LS; Filkowski MM; Ghaemi SN J Affect Disord; 2008 Sep; 110(1-2):70-4. PubMed ID: 18272230 [TBL] [Abstract][Full Text] [Related]
16. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772 [TBL] [Abstract][Full Text] [Related]
17. [Present data and treatment schedule of aripiprazole in the treatment of schizophrenia]. Limosin F; Azorin JM; Krebs MO; Millet B; Glikman J; Camus V; Crocq MA; Costentin J; Daléry J Encephale; 2008 Jan; 34(1):82-92. PubMed ID: 18514155 [TBL] [Abstract][Full Text] [Related]
18. Aripiprazole augmentation for major depressive disorder: dosing patterns in a naturalistic treatment setting. Pae CU; Wang SM; Han C; Lee SJ; Patkar AA; Masand PS Int Clin Psychopharmacol; 2014 Mar; 29(2):116-9. PubMed ID: 24108149 [TBL] [Abstract][Full Text] [Related]
19. Aripiprazole in schizophrenia and schizoaffective disorder: A review. Stip E; Tourjman V Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550 [TBL] [Abstract][Full Text] [Related]
20. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. Thase ME; Jonas A; Khan A; Bowden CL; Wu X; McQuade RD; Carson WH; Marcus RN; Owen R J Clin Psychopharmacol; 2008 Feb; 28(1):13-20. PubMed ID: 18204335 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]